Phillips, D. C., Xiao, Y., Lam, L. T., Litvinovich, E., Roberts-Rapp, L., Souers, A. J., & Leverson, J. D. (2016). Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J.
Chicago-stil citatPhillips, D C., Y. Xiao, L T. Lam, E. Litvinovich, L. Roberts-Rapp, A J. Souers, och J D. Leverson. "Loss in MCL-1 Function Sensitizes Non-Hodgkin's Lymphoma Cell Lines to the BCL-2-selective Inhibitor Venetoclax (ABT-199)." Blood Cancer J 2016.
MLA-referensPhillips, D C., et al. "Loss in MCL-1 Function Sensitizes Non-Hodgkin's Lymphoma Cell Lines to the BCL-2-selective Inhibitor Venetoclax (ABT-199)." Blood Cancer J 2016.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.